Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-07-24
2007-07-24
Saeed, Kamal (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S400000, C514S406000, C544S140000, C548S333500, C548S374100, C548S375100
Reexamination Certificate
active
10702149
ABSTRACT:
Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment diseases, conditions and/or disorders herein.
REFERENCES:
patent: 4925846 (1990-05-01), Deacon et al.
patent: 4944790 (1990-07-01), Moser et al.
patent: 5134142 (1992-07-01), Matsuo et al.
patent: 5462960 (1995-10-01), Barth et al.
patent: 5470862 (1995-11-01), Lin et al.
patent: 5596106 (1997-01-01), Cullinan et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 5744491 (1998-04-01), Boigegrain et al.
patent: 5744493 (1998-04-01), Boigegrain et al.
patent: 5747524 (1998-05-01), Cullinan et al.
patent: 5925768 (1999-07-01), Barth et al.
patent: 6028084 (2000-02-01), Barth et al.
patent: 6100259 (2000-08-01), Xiang et al.
patent: 6344474 (2002-02-01), Maruani et al.
patent: 6355631 (2002-03-01), Bouchard et al.
patent: 6432984 (2002-08-01), Barth et al.
patent: 6476060 (2002-11-01), Lange et al.
patent: 6479479 (2002-11-01), Achard et al.
patent: 6509367 (2003-01-01), Martin et al.
patent: 6518264 (2003-02-01), Achard et al.
patent: 6531492 (2003-03-01), Lundy et al.
patent: 6566356 (2003-05-01), Achard et al.
patent: 2001/0027193 (2001-10-01), Achard et al.
patent: 2001/0053788 (2001-12-01), Lange et al.
patent: 2002/0019383 (2002-02-01), Achard et al.
patent: 2002/0019421 (2002-02-01), Biberman et al.
patent: 2002/0035102 (2002-03-01), Achard et al.
patent: 2002/0091114 (2002-07-01), Plot-Grosjean et al.
patent: 2002/0119972 (2002-08-01), Leftheris et al.
patent: 2002/0128302 (2002-09-01), Maruani et al.
patent: 2002/0188007 (2002-12-01), Barth et al.
patent: 2003/0003145 (2003-01-01), Abramovici et al.
patent: 2003/0055033 (2003-03-01), Achard et al.
patent: 2003/0114495 (2003-06-01), Finke et al.
patent: 2003/0139386 (2003-07-01), Cote et al.
patent: 2003/0199536 (2003-10-01), Thomas et al.
patent: 2004/0072833 (2004-04-01), Nakai et al.
patent: 2004/0077650 (2004-04-01), Dow
patent: 2004/0092520 (2004-05-01), Griffith
patent: 293220 (1994-08-01), None
patent: 1354884 (2003-10-01), None
patent: WO 96/02248 (1996-02-01), None
patent: WO 9614302 (1996-05-01), None
patent: WO 00/15609 (2000-05-01), None
patent: WO 01/24798 (2001-04-01), None
patent: WO 01/28557 (2001-04-01), None
patent: WO 01/29007 (2001-04-01), None
patent: WO 0129007 (2001-04-01), None
patent: WO 01/32629 (2001-05-01), None
patent: WO 01/32663 (2001-05-01), None
patent: WO 01/58450 (2001-08-01), None
patent: WO 01/85092 (2001-11-01), None
patent: WO 02 053565 (2002-07-01), None
patent: WO 02/076949 (2002-10-01), None
patent: WO 03/006007 (2003-01-01), None
patent: WO 03/007887 (2003-01-01), None
patent: WO 03/018060 (2003-03-01), None
patent: WO 03/020217 (2003-03-01), None
patent: WO 03/020314 (2003-03-01), None
patent: WO 03/026647 (2003-04-01), None
patent: WO 03/026648 (2003-04-01), None
patent: WO 03/027069 (2003-04-01), None
patent: WO 03/027076 (2003-04-01), None
patent: WO 03/027114 (2003-04-01), None
patent: WO 03027076 (2003-04-01), None
patent: WO 03/040107 (2003-05-01), None
patent: WO 03/051850 (2003-06-01), None
patent: WO 03/051851 (2003-06-01), None
patent: WO 03/075660 (2003-09-01), None
patent: WO 03/077847 (2003-09-01), None
patent: WO 03/078413 (2003-09-01), None
patent: WO 03/082190 (2003-10-01), None
patent: WO 03/082191 (2003-10-01), None
patent: WO 03/082256 (2003-10-01), None
patent: WO 03/082833 (2003-10-01), None
patent: WO 03/084943 (2003-10-01), None
patent: WO 03/086288 (2003-10-01), None
patent: WO 03/087037 (2003-10-01), None
patent: WO 03 095455 (2003-11-01), None
patent: WO 2004/012617 (2004-02-01), None
Obach, Drugs of Today 39(5), p. 301-338 (2003).
Muccioli et al., “Synthesis and Activity of 1,3,5-Triphenylimidazolidine-2,4-diones and 1,3,5-Triphenyl-2-thioxoimidazolidin-4-ones: Characterization of New CB1 Cannabinoid Receptor Inverse Agonists/Antagonists,” J. Med. Chem., vol. 49, pp. 872-882 (2006).
Lallemand et al., “SR147778, a CB1 Cannabinoid Receptor Antagonist, Suppresses Ethanol Preference in Chronically Alcoholized Wistar Rats,” Alcohol, vol. 39, pp. 125-134 (2006).
Ramirez et al., “Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation,” J. Neuroscience, 25(8), pp. 1904-1913 (2005).
Roger G. Pertwee, Current Medicinal Chemistry, 1999, vol. 6, pp. 635-664, “Pharmacology of Cannabinoid Receptor Ligands”.
Brian F. Thomas et al., The Journal of Pharmacology and Experimental Therapies, 1998, vol. 285, No. 1, pp. 285-292, “Comparative Receptor Binding Analyses of Cannabinoid Agonists and Antagonists”.
Tzavara, E.T., et al., “The CB1 Receptor Antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: Implications for Therapeutic Actions,”J Pharmacol, 138, 544-553 (2003).
Racz, I., et al., “A Critical Role for the Cannabinoid CB1 Receptors in Alcohol Dependence and Stress-Stimulated Ethanol Drinking,”J Neurosci, 23(6), 2453-2458 (2003).
Croci, T., et al., “Role of Cannabinoid CB1 Receptors and Tumor Necrosis Factor-α in the gut and systemic anti-inflammatory activity of SR 141716 (Rimonabant) in rodents,”Brit J Pharmacol, 140, 115-122 (2003).
DaSilva, G.E., et al., “Potentiation of Penile Erection and Yawning Responses to Apomorphine by Cannabinoid Receptor Antagonists in Rats,”Neurosci Let, 349, 49-52 (2003).
Wang, L., et al., “Endocannabinoid Signaling via Cannabinoid Receptor 1 is involved in Ethanol Preference and its Age-Dependent Decline in Mice,”PNAS, 100(3), 1393-1398 (2003).
Ruiu, S., et al., “Synthesis and Characterization of NESS 0327: A Novel Putative Antagonist of the CB1 Cannabinoid Receptor,”J Pharmacol Exp Therap, 306, 363-370 (2003).
Howlett, A.C., et al., “International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors,”Pharmacol Rev, 54, 161-202 (2002).
Gomez, R., et al., “A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding,”J. Neurosci, 22(21), 9612-9617 (2002).
Wiley, J.L., et al., “Novel Pyrazole Cannabinoids: Insights into CB1 Receptor Recognition and Activation,”J Pharmacol Exp Therap, 296(3), 1013-1022 (2001).
Lellemand, F., et al., “Effects of CB1 Cannabinoid Receptor Blockade on Ethanol Preference After Chronic Ethanol Administration,”Alcohol Clin Exp Res, 25(9), 1317-1323 (2001).
Pertwee, R.G., “Cannabinoids and the Gastronintestinal Tract,”Gut, 48, 859-867 (2001).
Pertwee, R.G., “Cannabinoid Receptor Ligands: Clinical and Neuropharmacological Considerations, Relevant to Future Drug Discovery and Development,”Exp. Opin. Invest. Drugs, 9(7), 1573-1571 (2000).
Hungund, B.L. and B.S. Basavarajappa, “Are Anadamide and Cannabinoid Receptors involved in Ethanol Tolerance? A Review of the Evidence,”Alcohol&Alcoholism. 35(2) 126-133, (2000).
Freedland, C.S., et al., “Effects of SR141716A, a Central Cannabinoid Receptor Antagonist, on Food-maintained Responding,”Pharmacol Biochem Behav, 67, 265-270 (2000).
Lan, R., et al., “Structure-Activity Relationships of Pyrazole Derivatives as Cannabinoid Receptor Antagonists”J. Med. Che.m, 42, 769-776 (1999).
Pertwee, R.G., “Pharmacology of Cannabinoid Receptor Ligands”Curr Med Chem, 6, 635-664 (1999).
Basavarajappa, B.S., et al., “Chronic Ethanol Administration Down-regulates Cannabinoid Receptors in Mouse Brain Synaptic Plasma Membrane,”Brain Res, 793, 212-218 (1998).
Thomas, B.F., et al., “Comparative Receptor Binding Analyses of Cannabinoid Agonists and Antagonists,”J Pharmacol Exp Therap, 285, 285-292 (1998).
Colombo, G., et al., “Appetite Suppression and Weight Loss after the Cannabinoid Antagonist SR141716,”Life Sci., 63, PL113-PL117 (1998).
Simiand, J., et al., “SR141716, a CB1 Cannabinoid Receptor Antagonist, Selectively Reduces Sweet Food Intake in Marmose,”Behav. Pharmacol., 9, 1
Dow Robert L.
Hammond Marlys
Freistein Andrew B.
Lappin Julie M.
Pfizer Inc.
Pfizer Products Inc.
Saeed Kamal
LandOfFree
Cannabinoid receptor ligands and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cannabinoid receptor ligands and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cannabinoid receptor ligands and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3737575